Use of factor IX complex in warfarin-related intracranial hemorrhage.
OBJECTIVE
Anticoagulation-treated patients presenting with intracranial hemorrhage, including subdural hematoma, epidural hematoma, subarachnoid hemorrhage, and intracerebral hemorrhage, require urgent correction of their coagulopathy to prevent worsening hemorrhage and to facilitate surgical intervention when necessary. In this study, we compared the use of fresh frozen plasma (FFP) with that of Factor IX complex concentrate (FIXCC) to achieve rapid correction of warfarin anticoagulation.


METHODS
Patients admitted to a tertiary care center with computed tomography-proven intracranial hemorrhage and a prothrombin time of more than 17 seconds were considered for inclusion in the study protocol. Complete data sets were obtained for eight patients randomized to treatment with FFP and five patients randomized to treatment with FFP supplemented with FIXCC. The prothrombin time and International Normalized Ratio were measured every 2 hours for 14 hours. Correction of anticoagulation was defined as an International Normalized Ratio of < or =1.3.


RESULTS
A difference in repeated International Normalized Ratio measurements during the first 6 hours of correction was observed between the FIXCC and FFP groups (P < 0.03). The rate of correction was greater (P < 0.01) and the time to correction was shorter (P < 0.01) for the FIXCC-treated group. No difference in neurological outcomes was detected between groups, but a higher complication rate was observed for the FFP-treated group.


CONCLUSIONS
The use of FIXCC accelerated correction of warfarin-related anticoagulation in the presence of intracranial hemorrhage.
Boulis
N M
NM
Department of Surgery, University of Michigan, Ann Arbor, USA.
Bobek
M P
MP
Schmaier
A
A
Hoff
J T
JT
D005164:Factor IX / Q000627:therapeutic use*; D015600:Glasgow Coma Scale; D006801:Humans; D007262:Infusions, Intravenous; D019934:International Normalized Ratio; D020300:Intracranial Hemorrhages / Q000188:drug therapy*; D010949:Plasma; D016896:Treatment Outcome; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects*
D014859:Warfarin; D005164:Factor IX